Cardinal Health has entered a feasibility and commercial option agreement with Centocor, Inc. to develop cell lines using Cardinal’s Gene Product Expression (GPEx) cell line engineering technology. Cardinal Health will use its GPEx technology to engineer cell lines expressing undisclosed Centocor monoclonal antibodies. Cardinal’s technology enables rapid genetic engineering of stable mammalian cell lines. These cell lines are used to produce human proteins and antibodies, known as bi...